Online first
Short communication
Published online: 2024-06-18
The DOAC score is associated with elevated growth differentiation factor 15 and 3-nitrotyrosine in atrial fibrillation: prediction of bleeding at one-year follow-up
Pubmed: 38973434
Abstract
Not available
References
- Aktan A, Güzel T, Aslan B, et al. Comparison of the real-life clinical outcomes of warfarin with effective time in therapeutic range and non-vitamin K antagonist oral anticoagulants: Insight from the AFTER-2 trial. Kardiol Pol. 2023; 81(2): 132–140.
- Apostolakis S, Lane DA, Guo Y, et al. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol. 2012; 60(9): 861–867.
- Aggarwal R, Ruff C, Virdone S, et al. Development and validation of the DOAC score: a novel bleeding risk prediction tool for patients with atrial fibrillation on direct-acting oral anticoagulants. Circulation. 2023; 148(12): 936–946.
- Wallentin L, Hijazi Z, Andersson U, et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014; 130(21): 1847–1858.
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42(5): 373–498.
- Mołek-Dziadosz P, Natorska J, Malinowski KP, et al. Elevated growth differentiation factor 15 is associated with echocardiographic markers of right heart overload in atrial fibrillation. Pol Arch Intern Med. 2023; 133(12): 16627.
- Mołek P, Chmiel J, Ząbczyk M, et al. Elevated 8-isoprostane concentration is associated with thromboembolic events in patients with atrial fibrillation. Int J Cardiol. 2022; 365: 1–7.
- Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3(4): 692–694.
- Hijazi Z, Oldgren J, Lindbäck J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016; 387(10035): 2302–2311.
- Matusik PT. Biomarkers and cardiovascular risk stratification. Eur Heart J. 2019; 40(19): 1483–1485.
- Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation. 2001; 104(2): 174–180.
- Drabik L, Wołkow P, Undas A. Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: association with thrombin generation, endothelial injury and platelet activation. Thromb Res. 2015; 136(2): 408–414.
- Janion-Sadowska A, Chrapek M, Konieczyńska M, et al. Altered fibrin clot properties predict stroke and bleedings in patients with atrial fibrillation on rivaroxaban. Stroke. 2019; 50(1): 185–188.
- Gorczyca-Głowacka I, Kapłon-Cieślicka A, Wełnicki M, et al. Rules for the use of reduced doses of non-vitamin K antagonist oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation. The opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society. Kardiol Pol. 2022; 80(12): 1299–1306.
- Turek Ł, Sadowski M, Janion-Sadowska A, et al. Left atrial appendage thrombus in patients referred for electrical cardioversion for atrial fibrillation: A prospective single‑center study. Pol Arch Intern Med. 2022; 132(5): 16214.
